✦ LIBER ✦

Medicaid and the Unconstitutional Dimensions of Prior Authorization

✍ Scribed by Jagan Nicholas Ranjan

Book ID: 124475307
Publisher: University of Michigan Law School
Year: 2002
Tongue: English
Weight: 954 KB
Volume: 101
Category: Article
ISSN: 0026-2234
DOI: 10.2307/1290550

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of the Burden of Prior Autho

Development of the Burden of Prior Authorization of Psychotherapeutics (BoPAP) Scale to Assess the Effects of Prior Authorization Among Texas Medicaid Providers

✍ Carolyn M. Brown; Esmond Nwokeji; Karen L. Rascati; Woodie Zachry; Glenn A. Phil 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 205 KB

Effects of prior authorization on statew

Effects of prior authorization on statewide medicaid non-stress testing claims

✍ Curtis Lowery; Helen Kay; Jonathon Norton; Judith McGhee 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Effects of a statewide prior authorizati

Effects of a statewide prior authorization program on medicaid obstetrical ultrasound claims

✍ Judith McGhee; Helen Kay; Jonathon Norton; Curtis Lowery 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 52 KB

PMH81 EXAMINING THE PERCEIVED BURDEN OF

PMH81 EXAMINING THE PERCEIVED BURDEN OF PRIOR AUTHORIZATION OF PSYCHOTHERAPEUTICS AMONG TEXAS MEDICAID PRESCRIBERS

✍ C Brown; KL Rascati; ED Nwokeji; ZD Corbell; GA Phillips; WM Zachry 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Impact of Medicaid Prior Authorization R

Impact of Medicaid Prior Authorization Requirement for COX-2 Inhibitor Drugs in Nebraska

✍ Mark V. Siracuse; Phillip J. Vuchetich 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

Prior authorization for biologic disease

Prior authorization for biologic disease-modifying antirheumatic drugs: A description of US medicaid programs

✍ Fischer, Michael A. ;Polinski, Jennifer M. ;Servi, Amber D. ;Agnew-Blais, Jessic 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

## Abstract ## Objective To evaluate state Medicaid prior authorization programs for biologic disease‐modifying antirheumatic drugs (DMARDs). ## Methods We obtained biologic DMARD prior authorization policy information from state Medicaid programs. Using aggregate Medicaid drug spending data, we